Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacomitinib + dextromethorphan
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dacomitinib (PF-00299804) is an irreversible small-molecule inhibitor of human epidermal growth factor receptors 1 (EGFR), 2 (HER2), and 4 (HER4). It is primarily developed for the treatment of non-small cell lung cancer. Dextromethorphan is a widely used antitussive agent that acts centrally to suppress cough by decreasing activity in the brain's cough center. In clinical pharmacokinetic studies, dacomitinib has been shown to significantly increase systemic exposure to dextromethorphan by inhibiting CYP2D6-mediated metabolism. This combination has been studied in healthy volunteers mainly for drug-drug interaction purposes rather than as a therapeutic regimen[1][3][7].
- Brand names
- Vizimpro
- Other names
- PF-00299804PF00299804PF 00299804dacomitinibdextromethorphan
02
Targets
SIGMAR1 (Sigma non-opioid intracellular receptor 1)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on dacomitinib + dextromethorphan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacomitinib + dextromethorphan.